Telehealth companies are expanding into obesity treatment, pairing GLP-1 drugs like Ozempic with lifestyle coaching. But according to NPR, the arrangement troubles primary care physicians. Employers are pressuring these telehealth providers to limit spending on the medications themselves—creating a fundamental conflict: the same company supporting weight-loss success has financial incentive to deny the drug that makes that success possible.

Listen to this story

Hear this and more stories in a personalized audio briefing.

Open The Chonkerton